Our Work in Antibiotic Research
For more than 80 years, MSD has contributed to the discovery and development of novel medicines and vaccines to combat infectious disease. Today, MSD is a global leader in antimicrobials with a proud heritage, broad portfolio and innovative pipeline.
OUR HISTORY
MSD’s Research Laboratories played a central role in the development of antimicrobials
MSD, in collaboration with Rutgers University, developed one of the first methods for mass production of penicillin
MSD markets a number of antibacterial, antifungal, and antiviral products and vaccines for the treatment or prevention of infectious diseases in markets around the globe
MSD IS COMMITTED TO:
Maintaining active R&D programs to address unmet medical needs in the prevention and treatment of infectious disease
Monitoring trends in antibacterial resistance as exemplified by our longstanding commitment to surveillance studies
Supporting responsible use of antimicrobials to help slow development of resistance and preserve current therapeutic options
Advocating for improvements in regulatory guidance and financial incentives to support and accelerate innovation in the development of new antimicrobials, vaccines, services and solutions
“MSD is one of the largest pharmaceutical companies with a continued focus on anti-infective research and development. We develop treatments for serious infections and promote appropriate use of these products. As such, the need for patient-centered antimicrobial stewardship (AMS) is fundamental to our work.”
– Elizabeth D. Hermsen, Head of Global
Antimicrobial Stewardship, MSD
FINDING SOLUTIONS TO ANTIMICROBIAL RESISTANCE
There is a critical need for solutions to manage the growing problem of antimicrobial resistance.
INNOVATION
Research and innovation will lead to the development of new antibiotics.
STEWARDSHIP
Antimicrobial stewardship promotes the appropriate use of antimicrobials to reduce resistance.
POLICY
Policies can help spur innovation and regulate the use of antibiotics.
OUR COLLABORATIONS
In addition to our own antimicrobial research efforts, MSD also works with scientists across the world.
Through its MSD Innovation Network (MINt), the company actively collaborates with leading scientists in the antimicrobial field to investigate novel therapeutic targets, evaluate new pathways for drug targeting and develop novel tools and technologies. MSD has a number of ongoing collaborations with scientists at universities including Harvard, Yale and Princeton.
THE RACE AGAINST RESISTANCE – A CONTEST WITH NO FINISH LINE
Dalya Guris, M.D., M.P.H., executive director, Clinical Research, MSD Research Laboratories, on leading our product development teams, a dedicated group of people committed to being one step ahead in the fight against disease-causing bacteria.
The Unique Role of Public Policy in Addressing Antimicrobial Resistance
Nicole Mahoney, director, Global Regulatory Policy, MSD, on how antimicrobial resistance is forcing policy makers to rethink the way diseases are managed, from how infections are diagnosed and tracked to how anti-infectives are developed and used.
ADDITIONAL INFORMATION
